Bexson Biomedical

At the second edition of Benzinga’s Psychedelics Capital Conference, held in sunny Miami, leaders from four major ketamine therapy companies shared their optimistic insights and guidance about the industry. Revitalist L&W’s Kathryn Walker (OTC: RVLWF), Jeffrey Becker (Bexson...

SEVALENT, Bexson Biomedical’s disrupting offer ready for the small molecule injectable market, received patent allowance by the USPTO for “Complexing Agent Salt Formulations of Pharmaceutical Compounds.”  The company’s formulation technology enables wearable, home...

Bexson Biomedical recently signed a deal with the Stevanato Group to develop a subcutaneous delivery system of ketamine. “SG EZ-be Pod,” a wearable device designed for administering subcutaneous drugs, would facilitate patient administration of medications outside of clinics...

Bexson Biomedical, a private company in the psychedelics space, has inked a new agreement with Stevanato Group, an Italian-based provider of drug delivery solutions. Bexson is currently developing an improved version of ketamine called BB106, which allows for subcutaneous delivery of the drug. The...

Pharmaceutical startup Bexson Biomedical confirmed Monday the closing an oversubscribed Series A funding round. The $4.8 million raise was led by Greyhouse Partners' Noetic Psychedelic Fund. Noetic advisor Warren Wright also agreed to join Bexson’s board of directors, supporting...